Class 2 Medicines Recall: SANTEN Oy (trading as Santen UK Limited) and parallel distributor, IKERVIS 1 mg/mL eye drops, emulsion and VERKAZIA 1 mg/mL eye drops, emulsion, EL (21)A/30
SANTEN Oy (trading as Santen UK Limited) are recalling the above batches of products as a precautionary measure due to detection of particles/crystals of the active pharmaceutical ingredient ciclosporin.
Company name
SANTEN Oy (trading as Santen UK Limited)
IKERVIS 1 mg/mL eye drops, emulsion, EU/1/15/990/001
| Batch number | Expiry date | Pack size | First distributed |
|---|---|---|---|
| 8K38Q | 03/2022 | 30 X 0.3ML | 26 Sep 2019 |
| 4L41F | 09/2022 | 30 X 0.3ML | 15 Nov 2019 |
| 8L28C | 11/2022 | 30 X 0.3ML | 17 Sep 2020 |
VERKAZIA 1 mg/mL eye drops, emulsion, EU/1/15/990/002
| Batch number | Expiry date | Pack size | First distributed |
|---|---|---|---|
| 1L14P | 05/2022 | 120 x 0.3ml | 29 Jan 2021 |
| 4L40H | 09/2022 | 120 x 0.3ml | 06 May 2021 |
| 6L04J | 10/2022 | 120 x 0.3ml | 02 Jul 2021 |
Parallel Distributors
Orifarm A/S
IKERVIS 1 mg/mL eye drops, emulsion, EU/1/15/990/001
| Batch number | Parallel Distributor’s Batch Number | Expiry date | Pack size | First distributed |
|---|---|---|---|---|
| 6L03F | 6L03F | 10/2022 | 30 x 0.3ml | 9th December 2020 |
Active Pharmaceutical Ingredient: ciclosporin
MDR number
268-08/21
Brief description of the problem
SANTEN Oy (trading as Santen UK Limited) are recalling the above batches of products as a precautionary measure due to detection of particles/crystals of the active pharmaceutical ingredient ciclosporin. These particles have been detected following microscopic evaluation during stability monitoring.
Following the completion of their investigations SANTEN Oy are recalling the above batches additional to those recalled on 15 September 2021 (Reference EL (21)A/22).
Advice for healthcare professionals
Stop supplying the above batches immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
The presence of particles may cause ocular irritation, eye pain and foreign body sensation. Whilst the Marketing Authorisation Holder have not received any reports of adverse reactions being caused by the presence of particles in the above batches, healthcare professionals should advise patients to report any suspected adverse reactions via the MHRA Yellow Card scheme.
Further Information
Santen UK Limited
For more information, please contact +44 (0)1727 615 110 or email enquiries@santen.co.uk
For medical information queries, please contact 0345 075 4863 or email medinfo@santen.co.uk
For supply queries, please contact AAH Customer services at 0344 561 8899
Orifarm A/S
For all enquiries please contact:
Paul Tobin (Responsible Person) on 07583577513 or email at paul.tobin@orifarm.com
Steven Cross (UK Parallel Import Sales Manager) on 07498975920 or email at steven.cross@orifarm.com
Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.
Download document
Updates to this page
Published 18 November 2021Last updated 18 November 2021 + show all updates
-
Updated batch numbers for IKERVIS 1 mg/mL eye drops, emulsion, EU/1/15/990/001
-
First published.